Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Liabilities and Shareholders Equity (2023 - 2025)

Onconetix (ONCO) has disclosed Liabilities and Shareholders Equity for 2 consecutive years, with $61.9 million as the latest value for Q3 2024.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 122.08% to $61.9 million in Q3 2024 year-over-year; TTM through Dec 2024 was $196.4 million, a 17.16% increase, with the full-year FY2023 number at $87.5 million, changed N/A from a year prior.
  • Liabilities and Shareholders Equity was $61.9 million for Q3 2024 at Onconetix, up from $59.5 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $87.5 million in Q4 2023 to a low of $22.5 million in Q1 2023.